
usd pm et
summari compani make market comprehens line product servic treat
price-to-earnings oper ep
risk assess reflect compani highli
competit industri character technolog
innov new market entrant rang
start-up establish medic product develop
compani must consist enhanc product
develop new one maintain competit stand
howev demand product immun econom
cycl tend exhibit stabl long-term unit price
fiscal year end dec ep estim base cfra
oper earn histor earn report
cash dividend paid last year
past perform indic futur perform reli upon
analysi prepar equiti analyst
pm stock trade
expect sale grow
billion follow rise
ew could rapidli expand margin cut
sg spend encourag
manag long-term focu
expect revenu growth slightli outpac
oper expens lead oper
margin compar
ew largest busi transcathet heart
valv therapi thvt busi
revenu expect grow
approxim roughli
billion sale continu adopt
expans transcathet aortic valv
increas competit
tavr market late caus ew lose
insignific amount market share
launch ultra centera
expect ew regain share
maintain lead market share
competit across cardiovascular product
intens longer-liv age world
popul aim address heart diseas
think thvt market particip benefit
expand market
ew share trade
ep room
appreci analysi especi given
recent product launch data
present march show
tavr provid superior non-inferior
outcom surgic altern ew
leader grow tavr space
continu innov view ew grow
 margin favor vs
commit could lead breakthrough
develop technolog
minimally-invas mitral tricuspid valv
replac technolog difficult
due anatom complex forecast
ew one first compani market
risk recommend target
includ market share loss key product
categori difficulti commerci
product pipelin possibl
expect futur market structur heart
therapi smaller anticip
target price reflect
multipl ep
estim higher end ew
five-year rang
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview corp ew develop manufactur market product
technolog design treat advanc stage cardiovascular diseas ew categor
product technolog three main area transcathet heart valv therapi thvt surgic heart
valv therapi shvt critic
ew leader transcathet heart valv replac technolog design nonsurg
replac heart valv edward sapien famili valv transcathet aortic heart valv
use treat patient heart valv diseas tradit open-heart surgeri
sub-optimal ew began offer transcathet heart valv patient commerci europ
unit state japan sale ew transcathet heart valv repres
net sale respect
shvt segment core product line carpentier-edward perimount pericardi valv platform
includ valv aortic mitral surgic valv replac ew leader shvt
includ product annuloplasti ring beating-heart mitral repair system ew acquir
harpoon medic inc decemb sale ew surgic tissu heart valv product
repres net sale respect
critic segment make hemodynam monitor system ew world leader
measur patient heart function fluid statu surgic intens care set hemodynam
monitor enabl clinician balanc suppli demand oxygen critic ill patient
play import role enhanc surgic recoveri enabl appropri tissu organ perfus
ultim enabl improv patient outcom surviv sale ew core
hemodynam product repres net sale
competit landscap cardiovascular diseas number one caus death world
top diseas term health care spend nearli everi countri cardiovascular diseas progress
tend worsen time often affect structur individu heart result
compani aim treat cardiovascular diseas highli profit face sever competit
cardiovascular segment medic technolog industri dynam subject signific
chang due cost-of-car consider regulatori reform industri custom consolid
thvt ew primari competitor includ plc boston scientif corpor abbott
laboratori shvt ew primari competitor includ plc
plc critic ew compet primarili varieti compani specif product line includ
inc pulsion medic system se lidco group plc
key maintain grow market share medic devic industri upkeep product
research develop program edward invest sizeabl portion sale effort
 spend million sale compar million
million expect compani continu invest heavili
ew make signific invest improv streamlin establish
transcathet aortic heart valv replac procedur addit ew make signific
invest develop transcathet heart valv technolog design treat mitral
tricuspid valv diseas structur heart condit valvular diseas difficult
treat aortic valv diseas therefor ew could stand benefit significantli pioneer one
first market therapi
financi trend revenu grew billion billion five-year
cumul annual growth rate compound-annual-growth-rate year end decemb adjust ep
compound-annual-growth-rate vs ew typic maintain net cash posit
gener posit free cash flow defin cash flow oper less capit expenditur free
cash flow million vs million compani capit structur posit
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
ew overvalu usd
neutral sinc februari technic indic ew
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
fundament outlook health care
equip sub-industri next month
neutral slightli posit continu
expect compani sub-industri
grow posit macro environ
compani gener benefit
laxer food drug administr fda
technolog advanc sub-industri
also mani product area
equip use non-elect procedur
howev valuat high industri
investor sentiment medic devic
compani appear shaken
volatil late think
higher valuat sub-industri
mostli warrant recent expand
margin robust revenu growth weaker
constant currenc basi expect
revenu sub-industri continu
rise high-single-digit low-double-digit
percentag driven continu pipelin
innov new product emerg market
expans speed new product
come market increas recent
year success effort
fda reduc approv time medic
devic time see price
pressur incess headwind medic
impact trade war appear mild
far medic equip compani
accord medic devic trade
tariff billion medic
technolog export septemb
although chines
govern seek lower health care cost
equip manufactur insul
industri
possibl threat state health
care system lawsuit texa
rule unconstitut
current expect upheld upon
appeal although decis could take
coupl year reach democrat
take control hous
repres think see
significantli lower level effort
republican trump administr
tri repeal
hospit spend larg driver medic
equip sale robust
strong economi
tax cut job act tcja individu
mandat roll think
hospit could see pressur lead
sale pressur medic equip
requir american health
insur without requir
expect lower number american
gener see posit long-term
fundament includ increas global
demand qualiti health care age
popul rise outlay lead
steadi flow innov product
 health equip
sub-index rose vs declin
base index
five-year market price perform
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
ep estim sale increas organ
million global transcathet heart valv therapi thvt busi
grew organ ew implement target commerci introduct
centera valv europ remain track obtain ce mark
sapien ultra system ew intend also control roll-out strategi
sapien ultra system encourag hear ew obtain
approv begin pivot trial studi compani pascal mitral
et cfra add share edward lifesci corpor
top portfolio ew target price
reflect multipl ep estim
peer faster growth within ew five-year rang expect
sale grow billion follow rise
see oper margin expect
continu organ growth rang transcathet
heart valv therapi thvt busi revenu although ew sale
growth moder recent quarter optimist upcom
product launch ew leader grow tavr transcathet aortic
valv replac space continu innov
increas competit tavr market would also note ew
sizeabl cash posit june offer firm greater
financi flexibl mani peer ew replac thermo fisher
scientif top portfolio /cathi seifert
analyst research note compani news
et cfra reiter buy opinion share
corpor ew lift target base
multipl ep estim near high-end
ew five-year rang rais price target
forward earn multipl today posit data present
weekend ew sapien transcathet aortic valv replac tavr system
result studi show sapien superior
non-inferior surgic aortic valv replac savr tavr demonstr
lower rate all-caus death stroke rehospit primari
endpoint studi given result studi expect
market tavr expand rapidli origin anticip
especi patient low surgeri risk lift ep
estim higher growth expect /kevin huang cfa
pm et cfra add share health corpor top
portfolio ew think cvs-aet combin
tremend upsid potenti aet rapidli grow exposur
medicar advantag plan plan redesign in-stor experi
pharmaci custom merger also elimin risk lose aet
busi revenu enabl incentiv aet
million health plan particip use servic share
current trade ep estim appear discount us
replac ew top portfolio
et cfra keep buy opinion share
corpor ew rais target
above-p ep estim higher-end
ew five-year rang favor view ew exposur
nascent minimally-invas mitral tricuspid replac repair market
maintain ep estim introduc
ew post ep vs match consensu sale rose
driven growth global transcathet heart valv therapi
thvt busi surgic structur heart sale grew healthi aortic
unit volum adopt newer premium aortic valv critic
sale increas gross margin widen reflect
better mix fx continu favor view ew leadership posit
structur heart therapi market expect market rapidli expand
upon present data trial march
expect posit ew kevin huang cfa angelo zino cfa
pm et cfra lower opinion share buy
strong buy ew rais target
above-p ep estim continu
favor view ew leadership posit structur heart therapi market
expect market rapidli expand upon present data
trial march expect posit ew share
ew trade approxim morn news settlement
ew agre pay million settl
long-stand patent disput europ part
settlement compani agre litig disput relat
transcathet aortic valv certain mitral valv repair devic left
atrial appendag closur devic view posit
compani clear air enabl two medic devic
manufactur focu effort capit rapidli grow
lifesci ew keep target
above-p ep estim multipl
higher end ew five-year rang favor
view ew exposur nascent minimally-invas mitral tricuspid
replac repair market ep vs higher
estim rais ep estim
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim ew earn
usd fiscal year analyst estim
ew earn per share grow usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
